Paper Details
- Home
- Paper Details
[Dihydropyrimidine dehydrogenase deficiency causes severe adverse effects of capecitabine].
Author: AndouAkira, BambaHiromichi, ImaiTakayuki, InoueHiroto, KomaiYasunobu, NakamuraTomoaki, SatoYuto, ShintaniShuuhei, TanabeHiroki
Original Abstract of the Article :
We report the case of a 61-year-old man who experienced severe adverse effects of capecitabine because of dihydropyrimidine dehydrogenase (DPD) deficiency. In 2016, he visited our hospital for adenocarcinoma of the gastroesophageal junction and was prescribed neoadjuvant chemotherapy with capecitabi...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.11405/nisshoshi.115.290
データ提供:米国国立医学図書館(NLM)
The Hidden Dangers of Capecitabine: A Case Study of Dihydropyrimidine Dehydrogenase Deficiency
Capecitabine, a widely used chemotherapy drug, is a powerful weapon in the fight against cancer. However, this research highlights a rare but potentially life-threatening side effect: dihydropyrimidine dehydrogenase (DPD) deficiency. This case study tells the story of a 61-year-old man who experienced severe adverse effects after receiving capecitabine for adenocarcinoma of the gastroesophageal junction. This case highlights the critical importance of screening for DPD deficiency before administering capecitabine to patients.
Understanding the Risks of DPD Deficiency
The researchers discovered that the patient had extremely low levels of DPD protein, which is responsible for metabolizing 5-fluorouracil (FU), the active metabolite of capecitabine. This deficiency led to a buildup of FU, causing severe gastrointestinal toxicity, febrile neutropenia, and thrombocytopenia. The patient ultimately required a bowel resection due to hemorrhagic enteritis. This case emphasizes the need for routine testing for DPD deficiency to prevent such severe adverse events.
Navigating the Desert of Chemotherapy
This case study serves as a powerful reminder that even seemingly safe medications can have hidden risks. It's like encountering a hidden danger lurking in the desert of chemotherapy treatment. The research emphasizes the importance of careful patient selection and monitoring to minimize the risk of adverse events. It also underscores the need for ongoing research to develop safer and more effective treatment options for patients with cancer.
Dr.Camel's Conclusion
This case study highlights the importance of recognizing and managing DPD deficiency to ensure patient safety. It's like finding a hidden oasis of knowledge in the desert of chemotherapy treatment! By screening for this deficiency, we can better protect patients from severe side effects and ensure that they receive the most appropriate and effective treatment.
Date :
- Date Completed 2019-06-04
- Date Revised 2020-09-28
Further Info :
Related Literature
Japanese
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.